Radiesse 0.8ml

Radiesse Dermal Filler: A Comprehensive Overview

Radiesse dermal filler primarily consists of a synthetic form of Calcium Hydroxylapatite (CaHA) as its main and most crucial component. Specifically, CaHA particles make up 30% of Radiesse’s composition. In essence, these CaHA particles are synthesized from Ca2+ and PO3 ions, which are naturally occurring minerals found in bones and teeth. Due to this composition, CaHA is well-received by the human body and exhibits biological compatibility. Within Radiesse’s composition, the gel solution constitutes 70% and is formed from a mixture of cellulose gel with glycerin, water, and excipients. This gel solution serves as a carrier medium for the CaHA particles.

Approval for the use of Calcium Hydroxylapatite in the USA: CaHA has been widely used for a long time in various medical fields such as plastic surgery, otolaryngology, and dentistry. In the USA, the clinical application of CaHA Gel was first approved by the FDA in 1995. Preclinical long-term studies have been conducted with CaHA particles of 75-125 microns, injected around the urethra.

Approval for the use of Radiesse in the USA: Radiesse was initially approved for use in the United States in 2001 for tissue augmentation with Calcium Hydroxylapatite (CaHA) particles ranging from 75-125 microns. Subsequently, from 2002 to 2005, Radiesse was used experimentally to treat nasolabial folds and soft tissue wrinkles. In December 2006, the US Food and Drug Administration (FDA) approved the use of Radiesse for wrinkle correction. In July 2009, the FDA also approved the use of Radiesse mixed with Lidocaine, a local anesthetic, for patient treatment.

Today, Radiesse is injected to address wrinkles, contour the face without surgery, and is effective in areas such as temples, cheeks, corners of the mouth, jawline, chin, nasolabial folds, nasal spine, and nasal bridge, providing immediate results that last up to 36 months.

Mechanism of action of Radiesse: The CaHA particles are biocompatible and capable of providing longer-lasting aesthetic results compared to dermal fillers primarily composed of Hyaluronic Acid (such as Restylane, Juvederm), although the results are not permanent. CaHA particles gradually degrade over time into calcium and phosphate ions through the body’s metabolic processes. The efficacy of treatment depends on various factors such as age, treatment area, metabolic rate, leading to varying treatment outcomes among different patients.

The miraculous effectiveness of Radiesse in daily life: The latest generation of Radiesse is composed of uniformly shaped and sized CaHA particles with diameters ranging from 25-45 microns, providing minimal downtime and long-lasting aesthetic results of at least 12-18 months. Radiesse stimulates the body to produce natural collagen, and over time, the gel is absorbed while the CaHA particles support the growth of surrounding tissues within the skin, creating a new layer of dermal tissue. The growth of tissues varies among individuals and depends on various factors.

Safety of Radiesse treatment (FDA approved): The US Food and Drug Administration (FDA) has granted Radiesse certification for quality and safety since 2006, the highest certification for medical products and devices serving human healthcare issued by the FDA/US Department of Health. Radiesse is a high-density dermal filler for contouring the nose, chin, and cheeks, reducing wrinkles without surgery, offering superior results at a lower cost compared to other dermal fillers currently on the market. When used for contouring and wrinkle correction, Radiesse provides immediate and long-lasting effects.